Inhibiting PSM?-induced neutrophil necroptosis protects mice with MRSA pneumonia by blocking the agr system.
Ontology highlight
ABSTRACT: Given its high resistance, enhanced virulence, and high transmissibility, community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) pneumonia is highly associated with high morbidity and mortality. Anti-virulence therapy is a promising strategy that bypasses the evolutionary pressure on the bacterium to develop resistance. RNAIII-inhibiting peptide (RIP), as an accessory gene regulator (agr)-specific inhibitor, significantly restricts the virulence of S. aureus and protects infected mice from death by blocking the agr quorum sensing system. The protective effects of RIP on the neutropenic mice completely disappeared in a neutrophil-deleted mouse infection model, but not in the macrophage-deleted mice. This result confirmed that the in vivo antibacterial activity of RIP is highly associated with neutrophil function. Phenol-soluble modulins (PSMs), as major leukocyte lysis toxins of CA-MRSA, are directly regulated by the agr system. In this experiment, PSM?1, 2, and 3 significantly induced neutrophil necroptosis by activating mixed lineage kinase-like protein (MLKL) phosphorylation and increasing lactate dehydrogenase release. The S. aureus supernatants harvested from the agr or psm? mutant strains both decreased the phosphorylation level of MLKL and cell lysis. PSM?1-mediated neutrophil lysis was significantly inhibited by necrosulfonamide, necrostatin-1, TNF? antibody, and WRW4. These results showed PSM?1 induced necroptosis depends on formylpeptide receptor 2 (FPR2)-mediated autocrine TNF?. Moreover, the neutrophil necroptosis induced by S. aureus was significantly suppressed and pneumonia was effectively prevented by the blockage of agrA and psm? expression levels. These findings indicate that PSM?-induced necroptosis is a major cause of lung pathology in S. aureus pneumonia and suggest that interfering with the agr quorum sensing signaling pathway is a potential therapeutic strategy.
SUBMITTER: Zhou Y
PROVIDER: S-EPMC5834619 | biostudies-literature | 2018 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA